Tokyo, June 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061731) titled 'Study of Beta-Blocker Therapy, Heart Rate Changes, and Blood Biomarkers After Myocardial Infarction' on June 1.
Study Type:
Observational
Primary Sponsor:
Institute - Hamamatsu University School of Medicine
Condition:
Condition - Acute myocardial infarction
Classification by malignancy - Others
Genomic information - YES
Objective:
Narrative objectives1 - The purpose of this study is to exploratorily investigate the association between sympathetic nervous system- and beta-adrenergic receptor-related biomarkers, heart rate trajectory, left ventricular remodeling indices, and heart failure-related events, with a focus on beta-blocker therapy, in patients after acute myocardial infarction.
Basic objectives2 - Safety,Efficacy
Eligibility:
Age-lower limit - 18
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Patients who are 18 years of age or older at the time of consent.
Patients diagnosed Acute myocardial infarction introduced to beta-blocker.
Patients who have been fully informed of the study and who have given written consent of their own free will.
Key exclusion criteria - Patients with significantly poor medication adherence
Patients with advanced cancer
Patients with a history of autoimmune disease.
Patients deemed inappropriate by the attending physician, etc.
Target Size - 100
Recruitment Status:
Recruitment status - Enrolling by invitation
Date of protocol fixation - 2026 Year 05 Month 01 Day
Date of IRB - 2026 Year 02 Month 06 Day
Anticipated trial start date - 2026 Year 06 Month 01 Day
Last follow-up date - 2031 Year 01 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000070649
Disclaimer: Curated by HT Syndication.
